Ipamorelin Dosage in the Published Research Literature

Ipamorelin Half-Life and Dosing Frequency

Johansen et al. (1998, PMID 9879640) characterized the pharmacokinetics of ipamorelin and related peptides in male rats following intravenous bolus administration. Plasma concentration declined biexponentially. Systemic clearance was approximately 5-fold lower than GHRP-6 under the same conditions. Between 60–80% of the administered dose was recoverable from bile and urine as intact peptide, indicating moderate metabolic stability relative to earlier GHRPs — attributable to the non-natural amino acid residues (Aib, D-2-Nal, D-Phe) that confer protease resistance ^[9].

Intranasal bioavailability was approximately 20% in the rat IV-to-intranasal comparison in the same study ^[9]. No subcutaneous bioavailability figure for ipamorelin has been published in the peer-reviewed literature.

The biexponential plasma decay and the pulsatile GH-release profile together underpin the multiple-injection-per-day approach seen in published rodent protocols — the short duration of each GH pulse is consistent with the premise that repeated dosing is required to sustain downstream IGF-1 elevation over a multi-week study ^[3][4][8].

Human pharmacokinetic data for subcutaneous ipamorelin does not exist in the published literature. The ipamorelin half-life context above is rat IV data; any application to human subcutaneous protocols involves extrapolation not supported by published human PK studies.

Ipamorelin Half-Life

Ipamorelin has a short plasma half-life; plasma concentration declines biexponentially after IV bolus in rats (Johansen et al. 1998, PMID 9879640) ^[9]. The brief duration supports the pulsatile dosing approach used in most published protocols — multiple injections daily rather than a single daily dose. Human pharmacokinetic data is sparse; the Phase 2 trial used IV infusion, not subcutaneous injection, and did not report half-life measurements directly.

Published Research Dose Ranges

The following doses appear in the published peer-reviewed record. All are research contexts, not clinical recommendations.

Ipamorelin Research Dose Fractionation

Published animal studies use per-injection doses scaled to body weight, administered multiple times daily. The Andersen 2001 protocol used three injections daily; the Malmlöf 1999 protocol used four daily IV doses; the Venkova 2009 GI motility model used four IV doses at 3-hour intervals ^[4][6][8]. Human-framed research protocols vary; the distinction between per-dose and per-day totals is protocol-dependent and not standardized across the published literature.

Timeline of Observed Effects in Research Literature

In animal models, acute GH elevation is observed within 15–30 minutes of subcutaneous or intravenous administration; the pulse resolves within a few hours. Downstream IGF-1 changes have been measured after multi-week dosing protocols — the Andersen 2001 bone study ran 3 months; the Johansen 1999 bone growth study ran 15 days ^[3][4]. Human timeline data from controlled trials is not available for GH, IGF-1, or anabolic endpoints.

Ipamorelin Timing and Sleep

GH is naturally released during slow-wave sleep. Pre-sleep administration of GH secretagogues has been studied for alignment with physiologic GH rhythms — the rationale being that ipamorelin's pulse would coincide with the nocturnal GH surge rather than working against it. Fasting-state administration is also documented in some protocols to minimize somatostatin tone, which rises postprandially and blunts the GH response. No head-to-head timing comparison trial has been published for ipamorelin specifically; pre-sleep and fasting rationales derive from general GH physiology rather than ipamorelin-specific trial data.

Cycling Protocols and Receptor Desensitization

Receptor desensitization with prolonged GHS use has been studied in preclinical models. Jiménez-Reina et al. (2002) showed that 21-day chronic ipamorelin treatment in young female rats did not produce tachyphylaxis — somatotrophs from treated animals showed enhanced (not diminished) GH response to subsequent in vitro ipamorelin challenge ^[7]. This suggests desensitization is not an inevitable outcome at the durations studied. Whether longer exposure periods or higher doses produce receptor downregulation is not established in published literature. Controlled human data on optimal cycle length is not available.

Biomarker Monitoring in Ipamorelin Research

IGF-1 is the primary downstream marker used in published GH-secretagogue studies — a measurable proxy for cumulative GH pulse exposure. ACTH and cortisol panels appear in the selectivity research (Raun et al. 1998) as safety assessments confirming ipamorelin's sparing profile ^[1]. Glucose and insulin sensitivity have been measured in some GH-axis intervention studies, though not in published ipamorelin-specific trials. No dedicated ipamorelin biomarker monitoring protocol has been published in peer-reviewed literature.

Routes of Administration in the Published Literature

Three routes have been documented in published ipamorelin research:

Intravenous — the primary route in the Raun 1998 selectivity paper, the Malmlöf 1999 glucocorticoid model, the Venkova 2009 GI ileus model, and the NCT00672074 Phase 2 human trial. Most acute pharmacokinetic and GH-release characterization data uses IV administration ^{[1][6][8][11]}.

Subcutaneous — used in the Johansen 1999 bone growth study (three daily injections), the Andersen 2001 glucocorticoid bone model (three daily injections), and the Svensson 2000 bone mineral content study (osmotic minipump continuous delivery) ^[3][4][5]. The most common route in preclinical anabolic outcome studies.

Intranasal — approximately 20% bioavailability in male rats (Johansen et al. 1998), studied as a potential non-injection delivery option ^[9]. Not further evaluated in published outcome studies.